A case report of fludarabine associated ectopic atrial bradycardia and literature review of fludarabine induced bradycardia.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardio-oncology Pub Date : 2024-08-09 DOI:10.1186/s40959-024-00253-x
Steve Kong, Sanjana Nagraj, Dennis L Cooper, Kevin J Ferrick, Lili Zhang
{"title":"A case report of fludarabine associated ectopic atrial bradycardia and literature review of fludarabine induced bradycardia.","authors":"Steve Kong, Sanjana Nagraj, Dennis L Cooper, Kevin J Ferrick, Lili Zhang","doi":"10.1186/s40959-024-00253-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fludarabine is a chemotherapeutic agent with lymphodepleting effects that is increasingly used as part of a conditioning regimen prior to allogeneic stem cell transplantation. Fludarabine is generally considered a relatively safe medication with only rare cases of cardiotoxic side effects.</p><p><strong>Case presentation: </strong>Here, we present a case of a 30-year-old woman who was undergoing conditioning for a haploidentical cell transplantation for treatment of Fanconi anemia with a 5-day course of daily fludarabine infusion. After her second fludarabine infusion, she was noted to have ectopic atrial bradycardia that resolved with supportive therapy and completion of fludarabine infusion.</p><p><strong>Conclusion: </strong>We report the first case of ectopic atrial bradycardia associated with fludarabine. Although rare and transient, clinicians should recognize this rare cardiotoxic side effect of fludarabine.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11312176/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00253-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fludarabine is a chemotherapeutic agent with lymphodepleting effects that is increasingly used as part of a conditioning regimen prior to allogeneic stem cell transplantation. Fludarabine is generally considered a relatively safe medication with only rare cases of cardiotoxic side effects.

Case presentation: Here, we present a case of a 30-year-old woman who was undergoing conditioning for a haploidentical cell transplantation for treatment of Fanconi anemia with a 5-day course of daily fludarabine infusion. After her second fludarabine infusion, she was noted to have ectopic atrial bradycardia that resolved with supportive therapy and completion of fludarabine infusion.

Conclusion: We report the first case of ectopic atrial bradycardia associated with fludarabine. Although rare and transient, clinicians should recognize this rare cardiotoxic side effect of fludarabine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与氟达拉滨相关的异位心房性心动过缓病例报告和氟达拉滨诱发心动过缓的文献综述。
背景:氟达拉滨是一种具有淋巴清除作用的化疗药物,越来越多地被用作同种异体干细胞移植前调理方案的一部分。一般认为,氟达拉滨是一种相对安全的药物,只有极少数病例会出现心脏毒性副作用:在此,我们介绍一例 30 岁女性的病例,她正在接受治疗范可尼贫血的单倍体细胞移植,每天输注氟达拉滨,疗程为 5 天。在第二次输注氟达拉滨后,她出现异位性心房过缓,经过支持治疗和完成氟达拉滨输注后,异位性心房过缓症状消失:结论:我们报告了首例与氟达拉滨相关的异位性心房过缓。结论:我们报告了第一例与氟达拉滨相关的异位性心房过缓,尽管这种情况罕见且为一过性,但临床医生仍应认识到氟达拉滨这种罕见的心脏毒性副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardio-oncology
Cardio-oncology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
5.00
自引率
3.00%
发文量
17
审稿时长
7 weeks
期刊最新文献
Enhancing nurse competence in early recognition of cardiotoxicity. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: an updated systematic review and meta-analysis. Routine Ankle-Brachial Index (ABI) measurement: a window into atherosclerosis and early left ventricular dysfunction in patients diagnosed with cancer. Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users- a multi-center retrospective study. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1